Vanda Pharmaceuticals Inc

NASDAQ:VNDA 4:00:00 PM EDT

4.72

-0.06 (-1.25%)

5:25:23 PM EDT: $4.72 0.00 (-0.02%)

Market Cap (Intraday)	278.19M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$54.77 Million
Adjusted EPS	-$0.36

See more estimates

10-Day MA	$4.64
50-Day MA	$4.40
200-Day MA	$4.63

See more pivots

Vanda Pharmaceuticals Inc Stock, NASDAQ:VNDA

2200 Pennsylvania Avenue Northwest, Suite 300 E, Washington, District of Columbia 20037

United States of America

Phone: +1.202.734.3400

Number of Employees: 368

http://www.vandapharma.com

Description

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.